Search

Your search keyword '"Oualla K"' showing total 31 results
Start Over Author "Oualla K" Publisher elsevier bv
31 results on '"Oualla K"'

21. Stomach cancer: a descriptive study of 172 cases

Author

Messoudi, K., primary, Oualla, K., additional, Erraichi, H., additional, Berrad, S., additional, Boujarnija, R., additional, Amaadour, L., additional, Benbrahim, Z., additional, Arifi, S., additional, and Mellas, N., additional

Published
2019
Full Text
View/download PDF

27. Management of local and locoregional triple-negative breast cancer

Author

Messoudi, K., primary, Zouiten, O., additional, Oualla, K., additional, Bedoudou, H., additional, Acharfi, N., additional, Erraichi, H., additional, Berrad, S., additional, Amaadour, L., additional, Benbrahim, Z., additional, M’rabet, F., additional, Arifi, S., additional, and Mellas, N., additional

Published
2018
Full Text
View/download PDF

29. 25 Impact of bleomycin (BLM) administration on the development of pulmonary toxicity in advanced germ cell tumours (GCT) receiving first-line chemotherapy (CT): A meta-analysis of randomized studies

Author

Necchi, A., primary, Oualla, K., additional, Miceli, R., additional, Sonpavde, G., additional, Nicolai, N., additional, Raggi, D., additional, Giannatempo, P., additional, Boffi, R., additional, Busia, A., additional, Mariani, L., additional, and Salvioni, R., additional

Published
2016
Full Text
View/download PDF

31. Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies

Author

Nicola Nicolai, Guru Sonpavde, Daniele Raggi, Andrea Necchi, Roberto Boffi, Karima Oualla, Luigi Mariani, Rosalba Miceli, Alessandra Busia, Patrizia Giannatempo, Roberto Salvioni, Necchi, A, Miceli, R, Oualla, K, Sonpavde, G, Giannatempo, P, Raggi, D, Nicolai, N, Boffi, R, Busia, A, Mariani, L, and Salvioni, R

Subjects
Lung Diseases, Male, Oncology, medicine.medical_specialty, Pulmonary toxicity, Urology, medicine.medical_treatment, 030232 urology & nephrology, Bleomycin, 03 medical and health sciences, chemistry.chemical_compound, Clinical Trials, Phase II as Topic, 0302 clinical medicine, Internal medicine, medicine, Humans, Neoplasm Metastasis, Testicular cancer, Randomized Controlled Trials as Topic, Chemotherapy, Univariate analysis, Antibiotics, Antineoplastic, business.industry, Odds ratio, Neoplasms, Germ Cell and Embryonal, medicine.disease, Clinical trial, Treatment Outcome, Clinical Trials, Phase III as Topic, chemistry, 030220 oncology & carcinogenesis, Germ cell tumors, business
Abstract

In a trial-level meta-analysis of randomized studies, bleomycin administration was independently significantly associated with the development of pulmonary toxicity in patients with metastatic germ cell tumors receiving first-line chemotherapy. This effect was mainly seen with respect to all-Grade pulmonary toxicity. This study provided a further argument in favor of reducing the burden of curative chemotherapy in these highly curable malignancies. Background: Limited information is available about the effect of bleomycin administration on the development of pulmonary toxicity in metastatic germ cell tumors (GCT). Patients and Methods: A literature search was conducted to identify randomized trials of first-line chemotherapy for GCT. We conducted univariate and multivariate analyses using random effects models to evaluate the predictive role of bleomycin administration in the development of all Grade and Grade 3 to 4 (G3-4) pulmonary toxicity. The results were adjusted for length of follow-up, prognostic risk group, year of treatment, presence of lung metastases, and primary mediastinal GCT. Results: Fifty-three study arms of 25 phase II and III trials encompassing 6498 patients were selected: 40 that used bleomycin (n = 5093) and 13 that did not (n = 1405). The pooled probability of all-Grade pulmonary toxicity in the bleomycin and nonbleomycin arms was 11.7% (95% confidence interval [CI], 8.4%-16.0%) and 1.7% (95% CI, 0.7%-4.2%), respectively. Univariate analysis indicated that bleomycin administration was associated with the incidence of all-Grade (odds ratio [OR], 7.57; 95% CI, 2.84-20.18; Wald test P < .001) and G3-4 pulmonary toxicity (OR, 5.19; 95% CI, 1.57-17.16; P = .007). Multivariate analysis showed a significant association of bleomycin administration with the incidence of all-Grade pulmonary toxicity (OR, 4.14; 95% CI, 1.36-12.59; P = .012) and a trend toward significance for G3-4 toxicity (OR, 2.24; 95% CI, 0.91-5.51; P = .080). Conclusion: We quantified the bleomycin-associated effect on the development of pulmonary toxicity in patients with GCT who received first-line chemotherapy. This information might be useful for planning clinical trials aimed at reducing chemotherapy as well as to inform patients in the clinic. (C) 2016 Elsevier Inc. All rights reserved.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results